Skip to content
Menu

Scientific Research

Scientific Research
July 17, 2025
Yale Researchers Develop Novel Antibody-RNA Therapy for Resistant Cancers

A specially engineered antibody capable of delivering RNA therapies to hard-to-reach, treatment-resistant tumors significantly shrank tumor size and improved survival in animal models, according to a study published July 16 in Science Translational Medicine. The study provides evidence that, once injected into the bloodstream, the antibody TMAB3, combined with a type of RNA that stimulates an innate immune reaction, can localize to tumors and penetrate and destroy stubborn diseased cells in pancreatic, brain, and skin cancers. The research reported in this news article was supported by the National Institutes of Health, the Damon Runyon Cancer Research Foundation; the American Association for Cancer Research; Pew Cancer Research Scholars; Cancer Research Institute-Clinic & Laboratory Integration Program (CLIP); Yale Cancer Center; Blavatnik Fund for Innovation at Yale; Gennao Bio Sponsored Research Grant to Yale; and Yale University.

Scientific Research
July 3, 2025
Harvard Business School Announces Its 2025-2026 Blavatnik Fellows

Harvard Business School (HBS) has named its 2025-26 Blavatnik Fellows and the program’s twelfth cohort. Launched in 2013, the Blavatnik Fellowship in Life Science Entrepreneurship is part of a gift to Harvard University from the Blavatnik Family Foundation. The Blavatnik Fellowship offers HBS alumni and Harvard-affiliated postdoctoral researchers the opportunity to advance new ventures around promising life science technologies and develop their leadership talents during a 12-month fellowship year.

Scientific Research
July 2, 2025
Eight Translational Biotech Projects Selected for 2025 Blavatnik Accelerator Awards

The Blavatnik Fund for Innovation at Yale is pleased to announce the recipients of its 2025 Accelerator Awards, mid-cycle awards that support generating data for early-stage Yale life science research not typically funded by traditional research grants. This year’s awardees—eight research teams from across Yale—are addressing urgent challenges in cancer, ALS, inflammatory bowel disease, cardiovascular conditions, and rare genetic disorders and include innovative AI driven approaches to deliver faster drug development and better clinical trial outcomes.

Scientific Research
May 20, 2025
‘Smoldering’ Cardiovascular Crisis

Overall rates of premature deaths related to cardiovascular disease is down about 70 percent since its 1968 peak. Still, heart disease remains the leading cause of death for Americans. With help from Harvard’s Office of Technology Development (OTD), the University patented the new molecule and licensed it to Tectonic Pharmaceuticals, a company Kruse founded. Fewer than five years after the original prototype, Tectonic is now testing an updated version of Erlandson’s molecule in Phase 2 clinical trials. Harvard’s Blavatnik Biomedical Accelerator provided funding and business development support to advance the technology toward commercialization. Other technologies aim to treat other advanced stages of heart disease. With funding support from Harvard’s Blavatnik Biomedical Accelerator, stem cell and regenerative biology professor Richard T. Lee and engineering professor Jia Liu are co-developing a flexible, tissue-like device designed to both detect and stop atrial fibrillation — an irregular heart rhythm that can lead to stroke and heart failure. “If you could stop it before it gets going, then you really have something,” Lee said.

Scientific Research
May 15, 2025
Game-Changing $15 Million Gift Paves the Way for Future Biomedical Breakthroughs at NYU Langone

The Blavatnik Family Foundation’s Longtime Support of Pioneering Researcher Dr. Evgeny A. Nudler’s Work Holds Promise for Advances in Cancer Therapy, Antibiotic Resistance & Antiaging. NYU Langone Health today announced a $15 million gift from the Blavatnik Family Foundation to support research led by Evgeny A. Nudler, PhD, Julie Wilson Anderson Professor of Biochemistry in the Department of Biochemistry and Molecular Pharmacology and Investigator with the Howard Hughes Medical Institute. The gift will enable ongoing work in research areas that have already yielded decades of discoveries by Dr. Nudler’s team, including revelations on how genes are expressed and regulated, how bacteria resist antibiotics, and how cells execute continual DNA repair to prevent cancer and delay aging.

Blavatnik Awards
May 6, 2025
2025 Laureates of the Prestigious Blavatnik Awards for Young Scientists in Israel Announced

The Blavatnik Family Foundation, the Israel Academy of Sciences and Humanities, and The New York Academy of Sciences announced today the Laureates of the prestigious 2025 Blavatnik Awards for Young Scientists in Israel. This year’s Laureates, who will each receive US$100,000, are: Yonatan Stelzer, PhD (Life Sciences) – Weizmann Institute of Science, Benjamin Palmer, PhD (Chemical Sciences) – Ben-Gurion University of the Negev, and Chaim Garfinkel, PhD (Physical Sciences & Engineering) – The Hebrew University of Jerusalem. The 2025 Blavatnik Awards for Young Scientists in Israel will be conferred at a ceremony in June 2025 at the Peres Center for Peace & Innovation in Tel Aviv-Jaffa.

Scientific Research
March 13, 2025
Len Blavatnik: Family Offices ‘Should Invest’ to Power Growth of UK Life Sciences Sector

Philanthropists and family offices have a vital role to play by seizing the high-risk, high-reward opportunities that can lead to groundbreaking innovation, said Sir Leonard Blavatnik. Family offices are ideally placed to power the next generation of British biotech and life sciences companies, according to Sir Leonard Blavatnik. ‘Family offices should invest,’ said Sir Leonard, speaking exclusively to Spear’s at Kensington Palace, the venue for a gala dinner where the winners of the Blavatnik Awards for Young Scientists in the United Kingdom were announced last week.

Scientific Research
March 3, 2025
Blavatnik Therapeutics Challenge Awards Fuel Translational Research

Three research teams have been selected as recipients of the 2024 Blavatnik Therapeutics Challenge Awards, an annual awards program that aims to progress promising discovery science at Harvard Medical School toward the creation of new medicines that could be life-changing for patients. Now in its fifth and concluding year, the Blavatnik Therapeutics Challenge Awards have supported 20 research projects. Of the 17 projects awarded in the first 4 years of the program, four have already progressed to either the founding of a new company or licensing of the technology as part of a start-up. Two additional projects may enter clinical trials within the next year.

Scientific Research
February 24, 2025
Blavatnik Fund for Innovation at Yale to Support 15 Breakthrough Interventions in Cardiometabolic, Autoimmunity, Dermatology, and Oncology, and More

Since 2017, Yale and the Blavatnik Family Foundation have partnered to propel promising research beyond the university walls, bridging the gap between discovery and real-world application. Through the Blavatnik Fund for Innovation at Yale, a $65 million accelerator fund managed by Yale Ventures, 90 unique projects have led to 23 startups, 4 acquisitions, nine investigational new drug (IND) clearances, and work across diverse therapeutic modalities. This year’s fifteen awardees continue that legacy, tackling some of the most urgent life science challenges with projects spanning novel therapeutics to AI-powered medical solutions.

Scientific Research
February 24, 2025
Small Harvard Start-Up Launches to Fight Huge Problem of Antimicrobial Resistance

North Carolina biotech Kinvard Bio launched on Monday with a mission to develop next-generation drugs that can combat rising “superbugs.” Antimicrobial resistance (AMR) is one of the World Health Organization’s top public health concerns globally, claiming nearly 5 million lives per year. Kinvard’s launch on Monday was backed by the venture investment firm Kineticos Life Sciences, while much of the scientific groundwork done at Harvard was supported by the Blavatnik Biomedical Accelerator and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

Load More

Learn More

Discover the cutting-edge science we fund

Providing many of the world's best researchers, scientists, and universities with support, and funding to discover breakthroughs that solve humankind's greatest challenges.

See how we support great cultural institutions around the world

The Foundation contributes to renowned institutions that showcase the breadth of arts and culture, including performance, exhibition and education.

Visit the Blavatnik Archive

The Blavatnik Archive is a nonprofit foundation dedicated to preserving and disseminating materials that contribute to the study of 20th-century Jewish and world history, with a special emphasis on World War I, World War II, and Soviet Russia.

Back to Top
Blavatnik Family Foundation
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can find more information by this link